<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02856503</url>
  </required_header>
  <id_info>
    <org_study_id>20150288</org_study_id>
    <nct_id>NCT02856503</nct_id>
  </id_info>
  <brief_title>Effect of High Dose Vitamin D on Cancer Biomarkers and Breast Cancer Tumors</brief_title>
  <official_title>Phase I/II Study Evaluating Safety and Effects of Preoperative High-Dose Vitamin D on the Receptors, Biomarkers and Pathological Characteristics of High Grade DCIS or Invasive Breast Cancer.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Avisar</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Miami</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      High-doses of Vitamin D (VD) may be used as targeted therapy against breast cancer. The&#xD;
      investigators will assess the effect of high dose VD on the following biomarkers in the&#xD;
      breast cancer cells: VDR, estrogen receptor (ER), progesterone receptor (PR), epidermal&#xD;
      growth factor receptor 2 (Her2/neu), androgen receptor (AR), as well as epidermal growth&#xD;
      factor receptor 1 (EGFR) and Ki-67, as markers of proliferation, and E-cadherin, a marker of&#xD;
      invasion and metastasis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase I/II open-label, non-randomized study. In phase I, a fixed weekly course of&#xD;
      oral high-dose Vitamin D (VD) is planned for either 3, 4 or 5 weeks; patients will be&#xD;
      sequentially enrolled into 3 groups (A, B or C respectively) in a manner such that no more&#xD;
      than two patients may have treatment-limiting toxicities (TLTs).&#xD;
&#xD;
      After the group with the optimal duration of VD therapy to achieve a &quot;favorable response&quot; is&#xD;
      determined, phase II will begin enrollment.&#xD;
&#xD;
      Patients must be scheduled to have surgery performed within 2- weeks of the last dose of VD.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Lack of Funding&#xD;
  </why_stopped>
  <start_date type="Anticipated">January 2019</start_date>
  <completion_date type="Anticipated">January 2024</completion_date>
  <primary_completion_date type="Anticipated">January 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase 1 - Rate of Treatment-Related Toxicity in Subjects</measure>
    <time_frame>From Baseline to 30 days (+ 5 days) After Last Dose of Protocol Therapy, About 3 Months</time_frame>
    <description>Rate of treatment-related adverse events and other toxicities in subjects.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 2 - Rate of Favorable Treatment Response in Subjects Receiving Protocol Therapy Given Within the Optimal Duration Determined in Phase 1.</measure>
    <time_frame>Up to 7 Weeks</time_frame>
    <description>Rate of subjects achieving a &quot;favorable treatment response&quot; to protocol therapy given within the optimal duration determined in Phase 1. The effect of VD therapy will be assessed in terms of change in expression of VDR, ER, PR, HER2/neu, AR, Ki-67, E-cadherin and EGFR comparing surgical specimen (post-VD treatment) and baseline biopsy specimen (pre-VD treatment). The effect of VD will be described as increased expression, decreased expression or no change in expression of each marker/receptor measured.&#xD;
The expression of nuclear receptors/proteins (VDR, Ki-67, ER, PR, AR,) will be scored based on the percentage of positively staining nuclei as follows:&#xD;
0 (Negative) if &lt;1%&#xD;
+1 (Weak) if &gt;1-10%&#xD;
+2 (Moderate) if &gt;10-50%&#xD;
+3 (Strong) if &gt;50%&#xD;
A decrease in the expression of Ki-67 by ≥+1 after treatment is considered a &quot;favorable treatment response&quot;.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Phase 1 - Optimal Duration of Once-Weekly Protocol Therapy</measure>
    <time_frame>Up to 7 Weeks</time_frame>
    <description>The determination of the optimal duration of once-weekly protocol therapy, 3, 4 or 5 weeks, as preoperative treatment to achieve a &quot;favorable&quot; treatment response in subjects with the study disease. The effect of VD therapy will be assessed in terms of change in expression of VDR, ER, PR, HER2/neu, AR, Ki-67, E-cadherin and EGFR comparing surgical specimen (post-VD treatment) and baseline biopsy specimen (pre-VD treatment). The effect of VD will be described as increased expression, decreased expression or no change in expression of each marker/receptor measured.&#xD;
The expression of nuclear receptors/proteins (VDR, Ki-67, ER, PR, AR,) will be scored based on the percentage of positively staining nuclei as follows:&#xD;
0 (Negative) if &lt;1%&#xD;
+1 (Weak) if &gt;1-10%&#xD;
+2 (Moderate) if &gt;10-50%&#xD;
+3 (Strong) if &gt;50%&#xD;
A decrease in the expression of Ki-67 by ≥+1 after treatment is considered a &quot;favorable treatment response&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2 - Rate of Treatment-Related Toxicity in Subjects</measure>
    <time_frame>From Baseline to 30 days (+ 5 days) After Last Dose of Protocol Therapy, About 3 Months</time_frame>
    <description>Rate of treatment-related adverse events and other toxicities in subjects.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Invasive Breast Carcinoma</condition>
  <condition>Ductal Carcinoma In-situ</condition>
  <arm_group>
    <arm_group_label>Phase 1 - Group A - VD 3 Weeks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Weekly oral dose of 50,000 IU Vitamin D3 (VD) for 3 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 1 - Group B - VD 4 Weeks</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Weekly oral dose of 50,000 IU Vitamin D3 (VD) for 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 1 - Group C - VD 5 Weeks</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Weekly oral dose of 50,000 IU Vitamin D3 (VD) for 5 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2 - VD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Weekly oral dose of 50,000 IU Vitamin D3 (VD) therapy for the duration selected from the phase I part of the study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vitamin D3</intervention_name>
    <description>Weekly oral dose of Vitamin D3 per protocol.</description>
    <arm_group_label>Phase 1 - Group A - VD 3 Weeks</arm_group_label>
    <arm_group_label>Phase 1 - Group B - VD 4 Weeks</arm_group_label>
    <arm_group_label>Phase 1 - Group C - VD 5 Weeks</arm_group_label>
    <arm_group_label>Phase 2 - VD</arm_group_label>
    <other_name>Toxiferol</other_name>
    <other_name>Cholecalciferol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients must have histologically confirmed invasive breast carcinoma (IBC) or high&#xD;
             grade (DIN3) Ductal Carcinoma in-situ (DCIS) and be scheduled for primary surgery.&#xD;
&#xD;
          2. Patients must be recommended/scheduled for primary surgery.&#xD;
&#xD;
          3. Female patients 18 years of age or older.&#xD;
&#xD;
          4. Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2.&#xD;
&#xD;
          5. Patients must have normal organ function as defined below:&#xD;
&#xD;
               -  Aspartate aminotransferase (AST/SGOT) &lt; 4 times institutional upper limit of&#xD;
                  normal.&#xD;
&#xD;
               -  Alanine transaminase (ALT/SGPT) &lt; 4 times institutional upper limit of normal.&#xD;
&#xD;
               -  Serum Bilirubin &lt; 1.5 mg/dl.&#xD;
&#xD;
               -  Serum Alkaline Phosphatase &lt; 4 times institutional upper limit.&#xD;
&#xD;
               -  Creatinine within normal institutional limits OR; Creatinine clearance &gt;/= 60&#xD;
                  mL/min/1.73 m^2 for patients with creatinine levels above institutional normal.&#xD;
&#xD;
               -  Albumin within normal institutional limits&#xD;
&#xD;
          6. Women of childbearing potential (WoCBP) must have a negative (serum or urine)&#xD;
             pregnancy test and agree to use barrier contraception while on treatment and for&#xD;
             30-days thereafter.&#xD;
&#xD;
          7. Ability to understand and the willingness to sign a written informed consent document&#xD;
             by patient or their legal representatives.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Previous history of breast cancer diagnosis or treatment.&#xD;
&#xD;
          2. Synchronous bilateral breast cancer.&#xD;
&#xD;
          3. Metastatic breast cancer&#xD;
&#xD;
          4. Patients recommended for neoadjuvant systemic therapy.&#xD;
&#xD;
          5. Patients may not be receiving any other investigational agents or have participated in&#xD;
             any investigational drug study within 4 weeks preceding the start of study treatment.&#xD;
&#xD;
          6. Uncontrolled intercurrent illness including, but not limited to, ongoing or active&#xD;
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac&#xD;
             arrhythmia, or psychiatric illness/social situations that would limit compliance with&#xD;
             the study requirements.&#xD;
&#xD;
          7. Concurrent other malignancy&#xD;
&#xD;
          8. Uncontrolled hypertension&#xD;
&#xD;
          9. Chronic cholestatic or alcoholic liver disease&#xD;
&#xD;
         10. Chronic pancreatitis&#xD;
&#xD;
         11. Kidney impairment or renal stones&#xD;
&#xD;
         12. History of parathyroidectomy&#xD;
&#xD;
         13. Hypercalcemia, defined as serum level &gt;11 mg/dl.&#xD;
&#xD;
         14. Abnormal laboratory data for: AST (SGOT), ALT (SGPT), Serum Bilirubin, Alkaline&#xD;
             phosphatase, Creatinine and/or Creatinine clearance, and Albumin.&#xD;
&#xD;
         15. Patients receiving medications that are incompatible with VD.&#xD;
&#xD;
         16. Prior or known allergic reaction(s) to Vitamin D or other forms of Vitamin D.&#xD;
&#xD;
         17. Female patients who are pregnant or breast feeding.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eli Avisar, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Miami</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>August 2, 2016</study_first_submitted>
  <study_first_submitted_qc>August 2, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 5, 2016</study_first_posted>
  <last_update_submitted>January 16, 2019</last_update_submitted>
  <last_update_submitted_qc>January 16, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 18, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Miami</investigator_affiliation>
    <investigator_full_name>Eli Avisar</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>DCIS</keyword>
  <keyword>IBC</keyword>
  <keyword>Breast Cancer</keyword>
  <keyword>Invasive Breast Carcinoma</keyword>
  <keyword>High Grade Ductal Carcinoma in-situ</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Carcinoma in Situ</mesh_term>
    <mesh_term>Carcinoma, Ductal</mesh_term>
    <mesh_term>Carcinoma, Intraductal, Noninfiltrating</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

